Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2025-07-03 DOI:10.2174/0122117385407218250621220813

Parhan -, Rachmat Mauludin, Kusnandar Anggadiredja

{"title":"Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.","authors":"Parhan -, Rachmat Mauludin, Kusnandar Anggadiredja","doi":"10.2174/0122117385407218250621220813","DOIUrl":null,"url":null,"abstract":"Introduction: Intracellular calcium in pancreatic beta cells plays a crucial role in insulin synthesis and secretion. Diabetes impairs this calcium-mediated action, necessitating an effective delivery system such as liposomes to facilitate calcium uptake.Methods: Calcium lactate nanoliposomes (6.25 mg/mL) were prepared via the thin-film hydration method using lecithin and cholesterol as bilayer lipids. Their glucose-lowering efficacy was tested in hyperglycemic mice induced by oral glucose (1 g/kg) and intraperitoneal streptozotocin (45 mg/kg). Pancreatic calcium levels were measured using X-ray fluorescence to verify calcium delivery to beta cells.Results: The nanoliposomes exhibited a diameter of 172.1 nm, zeta potential of -53.45 mV, polydispersity index of 0.203, and pH 7.2. Entrapment efficiency was 93.42%, with stable pH and particle size over six cycles. Treatment with calcium nanoliposomes significantly reduced blood glucose levels in both diabetic and glucose-loaded mice. Pancreatic calcium concentrations were higher in animals receiving calcium nanoliposomes compared to controls.Discussion: Calcium nanoliposomes induced a significant glucose reduction relative to controls (empty liposomes, distilled water, and calcium in distilled water). Encapsulation within liposomal vesicles enhanced calcium delivery to pancreatic beta cells, increasing intracellular calcium and stimulating insulin production and release. This was corroborated by elevated pancreatic calcium levels observed via X-ray fluorescence in treated animals.Conclusion: Calcium nanoliposomes effectively improve glycemic control in diabetic and glucosechallenged animal models by enhancing calcium delivery to pancreatic beta cells.","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385407218250621220813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Intracellular calcium in pancreatic beta cells plays a crucial role in insulin synthesis and secretion. Diabetes impairs this calcium-mediated action, necessitating an effective delivery system such as liposomes to facilitate calcium uptake.

Methods: Calcium lactate nanoliposomes (6.25 mg/mL) were prepared via the thin-film hydration method using lecithin and cholesterol as bilayer lipids. Their glucose-lowering efficacy was tested in hyperglycemic mice induced by oral glucose (1 g/kg) and intraperitoneal streptozotocin (45 mg/kg). Pancreatic calcium levels were measured using X-ray fluorescence to verify calcium delivery to beta cells.

Results: The nanoliposomes exhibited a diameter of 172.1 nm, zeta potential of -53.45 mV, polydispersity index of 0.203, and pH 7.2. Entrapment efficiency was 93.42%, with stable pH and particle size over six cycles. Treatment with calcium nanoliposomes significantly reduced blood glucose levels in both diabetic and glucose-loaded mice. Pancreatic calcium concentrations were higher in animals receiving calcium nanoliposomes compared to controls.

Discussion: Calcium nanoliposomes induced a significant glucose reduction relative to controls (empty liposomes, distilled water, and calcium in distilled water). Encapsulation within liposomal vesicles enhanced calcium delivery to pancreatic beta cells, increasing intracellular calcium and stimulating insulin production and release. This was corroborated by elevated pancreatic calcium levels observed via X-ray fluorescence in treated animals.

Conclusion: Calcium nanoliposomes effectively improve glycemic control in diabetic and glucosechallenged animal models by enhancing calcium delivery to pancreatic beta cells.

查看原文本刊更多论文

钙纳米脂质体改善小鼠糖尿病模型的血糖控制。

胰腺细胞内钙在胰岛素的合成和分泌中起着至关重要的作用。糖尿病损害这种钙介导的作用，需要一个有效的输送系统，如脂质体，以促进钙的吸收。方法：以卵磷脂和胆固醇为双层脂质，采用薄膜水合法制备乳酸钙纳米脂质体（6.25 mg/mL）。采用口服葡萄糖（1 g/kg）和腹腔注射链脲佐菌素（45 mg/kg）对高血糖小鼠进行降糖试验。使用x射线荧光测量胰腺钙水平，以验证钙向β细胞的输送。结果：纳米脂质体直径为172.1 nm， zeta电位为-53.45 mV，多分散性指数为0.203，pH值为7.2。6次循环后，截留效率为93.42%，pH和粒径稳定。钙纳米脂质体治疗显著降低了糖尿病小鼠和葡萄糖负荷小鼠的血糖水平。与对照组相比，接受钙纳米脂质体治疗的动物胰腺钙浓度更高。讨论：相对于对照组（空脂质体、蒸馏水和蒸馏水中的钙），钙纳米脂质体诱导显著的葡萄糖减少。脂质体囊泡内的包封增强了钙向胰腺细胞的传递，增加了细胞内的钙，刺激了胰岛素的产生和释放。通过x射线荧光观察到的治疗动物胰腺钙水平升高证实了这一点。结论：钙纳米脂质体通过促进钙向胰腺β细胞的传递，有效改善糖尿病和糖挑战动物模型的血糖控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.